# Blue Jet Healthcare share price today (Blue Jet Healthcare Ltd, NSE: BLUEJET)

> Blue Jet Healthcare share price today: ₹531.85 at the NSE close on 4 November 2026, down 11.1% in a year. Blue Jet Healthcare (NSE: BLUEJET) is worth ₹10,058 crore, trades at a P/E of 42.8 and has closed between ₹343.80 and ₹626.25 over the past 52 weeks. > Blue Jet Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BLUEJET · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹531.85 (−11.1% in a year)
- P/E: 42.8× (higher than 57% of the last 3 years)
- Revenue (Jun 2026): ₹293 Cr (−17.5% on a year ago)
- Profit (Jun 2026): ₹78.0 Cr (−14.3% on a year ago)
- Operating margin: 33.0% (−1.0 points on a year ago)
- ROCE: 26%, FY26
- ROIC: 17.3%, against a 12.0% cost of capital: +5.3 points

The main question: domestic institutions moved +5.5 percentage points over 8 quarters while the business went the other way. ## What is the Blue Jet Healthcare share price today? Blue Jet Healthcare Ltd's share price was ₹531.85 at the close on 4 November 2026. It has been rising for 15 weeks. That is 1.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹344 and ₹626, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. Over the last 3 years the share price moved +36% while the NIFTY 500 moved +27%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Blue Jet Healthcare this quarter? Two changes stood out: revenue down on a year earlier for 4 quarters in a row and profit down on a year earlier for 4 quarters in a row. 1. Revenue down on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹293 crore, -17.5% on a year earlier. Why: Revenue fell because some contrast media sales were not counted yet. Customer contracts count sales on delivery, and container shortages and longer transit kept goods in transit. Next results: check whether the higher goods in transit are counted as sales next quarter. From the earnings call on 3 Aug 2026. 2. Profit down on a year earlier for 4 quarters in a row In the June 2026 quarter profit was ₹78 crore, -14.3% on a year earlier. Why: Profit fell because raw material costs rose and the mix of products sold was less favorable. Next results: check whether customer contracts reset prices as raw material prices settle. From the earnings call on 3 Aug 2026. ## What are Blue Jet Healthcare's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Blue Jet Healthcare reported revenue of ₹293 crore, down 17.5% from ₹355 crore a year earlier, and a profit of ₹78.0 crore, down 14.3% from ₹91.0 crore. ### Blue Jet Healthcare results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹293 crore | ₹355 crore | −17.5% |
| Profit | ₹78.0 crore | ₹91.0 crore | −14.3% |
| Earnings per share | ₹4.51 | ₹5.26 | −14.3% |
| Operating margin | 33.0% | 34.0% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Blue Jet Healthcare's management discussed these results on a call held on 3 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Blue Jet Healthcare share price history? Blue Jet Healthcare closed at ₹531.85 on 4 November 2026, down 11.1% from ₹598.15 a year earlier (7 November 2025) and up 36.4% over three years. Its highest weekly close since November 2023 was ₹1,010.20 on 18 July 2025. ### Blue Jet Healthcare share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹504.55 | +5.4% |
| 1 month ago · 1 Oct 2026 | ₹541.80 | −1.8% |
| 6 months ago · 8 May 2026 | ₹490.45 | +8.4% |
| 1 year ago · 7 Nov 2025 | ₹598.15 | −11.1% |
| 3 years ago · 3 Nov 2023 | ₹389.85 | +36.4% |
| Earliest weekly close in our records · 3 Nov 2023 | ₹389.85 | +36.4% |
| Highest weekly close since November 2023 · 18 Jul 2025 | ₹1,010.20 | −47.4% |
| Lowest weekly close since November 2023 · 2 Feb 2024 | ₹334.90 | +58.8% |
| 52-week high (weekly close) · 31 Jul 2026 | ₹626.25 | −15.1% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹343.80 | +54.7% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (162 weekly closes from 3 November 2023 to 4 November 2026.)

## What is the latest news on Blue Jet Healthcare? 4 Nov 2026: Blue Jet Healthcare closed at ₹531.85, up 5.4% on the week and down 1.8% on the month. 11 Sep 2026: ex-date for a dividend of ₹1.20 a share, record date 14 Sep 2026. ### Earlier

- 3 Aug 2026: Blue Jet Healthcare held its results call for April to June 2026. Management guided: PI/API: strong order book and very good visibility for at least the next 3 or 4 quarters. - Results for April to June 2026: Revenue down 17.5% and profit down 14.3% on a year earlier. ## What dividend does Blue Jet Healthcare pay? Blue Jet Healthcare paid ₹1.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.23% at the ₹531.85 close on 4 November 2026. The last was a dividend of ₹1.20 a share, ex-date 11 September 2026. ### Blue Jet Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 11 Sep 2026 | ₹1.20 | Dividend | 14 Sep 2026 |
| 19 Sep 2025 | ₹1.20 | Dividend | same day |
| 17 Sep 2024 | ₹1 | Dividend | 18 Sep 2024 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Blue Jet Healthcare Ltd paid out 8% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Blue Jet Healthcare management say on the latest results call? On the call for April to June 2026, held on 3 August 2026, Blue Jet Healthcare's management guided: PI/API: strong order book and very good visibility for at least the next 3 or 4 quarters. > “We will not participate in the patented generic peptide opportunity, where there is congestion and significant price erosion.”
> V.K. Singh, Chief Operating Officer, on the call for April to June 2026

### What management guided

- Contrast media: about ₹30 crore of higher goods in transit expected to be recognized next quarter; iodinated commercial batches planned by end-Q2 or beginning-Q3. - Unit 3 backward integration: commissioning later this calendar year, commercial contribution in H2 FY27, and asset-block addition above ₹200 crore at commercialization. - Vizag Phase 1: approximately ₹1,000 crore over 3 years; commercialization from end-FY29 to FY30, with ramp-up potentially in FY31 or FY32. - FY27 capital spending: approximately ₹250 crore was cited, while Q&A said a similar amount to the analyst's cited ₹400 crore plan; exact figure unresolved. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/50503/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 3 August 2026.)

## What to watch in Blue Jet Healthcare's next results? When Blue Jet Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: PI/API order-book execution - check whether supply continuity converts into sustained reported growth. - What to check (from the call)
- PI/API order-book execution - check whether supply continuity converts into sustained reported growth. - Contrast-media recognition and iodinated commercial batches - check logistics normalization and customer scale-up. - Capital spending execution at Unit 3 and Vizag - check commissioning, spending and customer-linked buildout against management's milestones. - Raw-material pass-through - check whether case-by-case contract resets begin as input prices stabilize. ## Which stock lists is Blue Jet Healthcare on? Blue Jet Healthcare is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 10066.727777227234](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Blue Jet Healthcare profitable? Blue Jet Healthcare Ltd earned ₹78.0 Cr of net profit in the Jun 2026 quarter, −14.3% on the same quarter a year earlier. Full-year FY26 profit was ₹248 Cr. Over 6 years profit has grown 9.4% a year on average. That is 26.6% of the quarter's revenue. The same quarter a year earlier earned ₹91.0 Cr. For the full year, FY26 profit was ₹248 Cr (−18.7% on the year before). Why profit moved: revenue changed −17.5% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −31.5% and revenue −27.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Blue Jet Healthcare make, and is it growing? Blue Jet Healthcare Ltd reported ₹293 Cr of revenue in the Jun 2026 quarter, −17.5% on the same quarter a year earlier. Over 6 years it has grown 9.9% a year on average. The last full year, FY26, came in at ₹947 Cr. The last four reported quarters add to ₹885 Cr. FY26 revenue was ₹947 Cr, −8.1% on the year before. Recent pace: the last four quarters grew −27.2% on average, against 9.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −27.5%, against +12.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −34.6%, against +21.7% a year (rolling over). ## How much of every ₹100 of sales does Blue Jet Healthcare keep? Blue Jet Healthcare Ltd's operating margin was 33.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 7 years it has been between 30.0% and 41.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed +4.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Blue Jet Healthcare's profit turning into cash? Over the last 3 years, 87% of Blue Jet Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹334 Cr of operating cash against ₹248 Cr of profit. After ₹252 Cr of spending on assets, ₹82.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 87% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 7.2× depreciation over three years. The next section checks what that spending is building. ## Where does Blue Jet Healthcare's cash go? Blue Jet Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 240 days in FY26, up from 231 days in FY21. It spent ₹506 Cr on assets over the last 3 years. Customers take 131 days to pay, and stock sits for 157 days on average. At FY26 sales of ₹947 Cr, each day of that cycle ties up about ₹2.6 Cr, so roughly ₹623 Cr is tied up in the business at any time. FY26: customers took 131 days to pay and stock sat for 157 days, about 5.2 months of sales sitting as stock, for a full cycle of 240 days, longer than FY21's 231. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 157 days. Customers pay about 131 days after that. Suppliers are paid at 48 days. Together that makes the 240-day cycle. Spending on assets: ₹506 Cr over the last 3 years, against ₹70.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹301 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Blue Jet Healthcare's P/E ratio, and how does it compare with its own history? Blue Jet Healthcare Ltd's P/E is 42.8×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 41.1×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹13.55. Why the multiple is where it is: over the past year earnings per share moved −18.8% while the price moved −11.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +10.9% a year; about +10.6% a year came from earnings growth and about +0.3 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Blue Jet Healthcare business getting better or worse? Blue Jet Healthcare Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −27.5% in the latest quarter, against +75.7% at its best in 12 quarters, with ROCE falling at 25.1%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Blue Jet Healthcare earn on its capital? Blue Jet Healthcare Ltd earned a ROCE of 26% in FY26. Its return on capital used (ROIC) is 5.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 26.2% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 26.2% net margin × 0.58× asset turnover × 1.21× leverage (assets divided by equity) ≈ 18.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 17.3% − 12.0% = +5.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 17.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 21.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Blue Jet Healthcare have too much debt? Blue Jet Healthcare Ltd has total debt of ₹42.0 Cr against shareholder equity of ₹1,360 Cr as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.00 in FY23 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Blue Jet Healthcare shareholding pattern? Promoters cut their stake in Blue Jet Healthcare Ltd by 12.8 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 73.2% of the company. Domestic institutions moved +5.5 points over the same period, to 7.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −12.8 points over 8 quarters, to 73.2%; Domestic institutions: +5.5 points over 8 quarters, to 7.5%; Foreign institutions: −0.3 points over 8 quarters, to 0.8%. Why the owners changed: promoters drove it (−12.8 points), with the other side taken by domestic institutions (+5.5 points). They reduced their stake. ## How far is Blue Jet Healthcare from balance-sheet trouble? For Blue Jet Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Blue Jet Healthcare rank in its industry? 52.7 out of 100, rank 12 of 24 in Pharma - API & CRAMS, with 81% of the evidence available. Blue Jet Healthcare Ltd scores 52.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 12. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 7.1 + 21.2 + 14.4 + 10 = 52.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Blue Jet Healthcare compared with? Blue Jet Healthcare ranks 12 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 52.7 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. Blue Jet Healthcare Ltd this page BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.1/35 · Revenue -27.5% · Profit -34.6% · Operating margin change -1 points · 88% evidence Capital efficiency 21.2/25 · ROCE 26.1% · Operating margin 33% · 100% evidence Valuation 14.4/20 · P/E 40.6× · PEG 1.39 · 100% evidence Relative strength 10.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.6% · 1 year -23.1% · 25% evidence · 7 of 12 weeks ahead Exact sum: 7.1 + 21.2 + 14.4 + 10 = 52.7 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Blue Jet Healthcare in size? Blue Jet Healthcare is the 16th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Syngene International, Jubilant Pharmova and Concord Biotech. Just below it: Supriya Lifescience, Morepen Laboratories and IOL Chemicals & Pharmaceuticals. ### Pharma - API & CRAMS companies close in size

1. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) ₹16,256 crore
2. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore
3. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore
4. Blue Jet Healthcare Ltd ₹9,550 crore
5. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) ₹6,819 crore
6. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore
7. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Can Fin Homes Ltd](https://www.sectoralpha.in/stocks/can-fin-homes-ltd) ₹9,582 crore · Finance - Housing
2. [Aptus Value Housing Finance India Ltd](https://www.sectoralpha.in/stocks/aptus-value-housing-finance-india-ltd) ₹9,580 crore · Finance - Housing
3. Blue Jet Healthcare Ltd ₹9,550 crore
4. [Inox Wind Ltd](https://www.sectoralpha.in/stocks/inox-wind-ltd) ₹9,540 crore · Capital Goods - Engineering Heavy
5. [Park Medi World Ltd](https://www.sectoralpha.in/stocks/park-medi-world-ltd) ₹9,490 crore · Hospitals/Medical Services

## What else do people ask about Blue Jet Healthcare? ### What is Blue Jet Healthcare's share price today? Blue Jet Healthcare Ltd's share price is ₹531.85, −11.1% over the past year. The whole company is worth ₹10,058 Cr on the market. In the last 52 weeks it traded between ₹344 to ₹626; today it is 67% of the way up from the low, 1.0% below its 200-day average (as of 4 November 2026). ### What were Blue Jet Healthcare's latest quarterly results? Blue Jet Healthcare Ltd reported revenue of ₹293 Cr and net profit of ₹78.0 Cr for the Jun 2026 quarter. Revenue fell 17.5% and profit fell 14.3% compared with a year earlier. Earnings per share were ₹4.51. The operating margin was 33.0%, 1.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Blue Jet Healthcare's market cap? Blue Jet Healthcare Ltd's market capitalisation is ₹10,058 Cr at a share price of ₹531.85. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Blue Jet Healthcare performing? Blue Jet Healthcare Ltd's share price has been rising for 15 weeks. In its latest quarter, revenue fell 17.5% and profit fell 14.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running (as of 4 November 2026). ### Will Blue Jet Healthcare's share price go up? This page does not forecast Blue Jet Healthcare Ltd's share price. What it shows instead: the share price is ₹531.85, and it has been rising for 15 weeks. Its P/E of 42.8× is higher than 57% of its own last 3 years (as of 4 November 2026). ### Who owns Blue Jet Healthcare? Promoters own 73.2% of Blue Jet Healthcare Ltd, foreign institutions 0.8%, domestic institutions 7.5% and the public 18.6% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 12.8 percentage points over 8 quarters (as of 4 November 2026). ### Does Blue Jet Healthcare have too much debt? No, Blue Jet Healthcare Ltd has little debt: its debt is 0.03× its equity, and its operating profit is 49 times its interest bill. FY26 borrowings were ₹44.0 Cr against equity of ₹1,360 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Blue Jet Healthcare in its business cycle? Blue Jet Healthcare Ltd's FY26 operating margin was 31.0%, against a 7-year range of 30.0% to 41.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 33.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Blue Jet Healthcare story? The main question: domestic institutions moved +5.5 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Blue Jet Healthcare a stock worth studying right now? What the numbers show: Blue Jet Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Blue Jet Healthcare share price forecast for 2026? What management itself guided: PI/API: strong order book and very good visibility for at least the next 3 or 4 quarters. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.